224 related articles for article (PubMed ID: 28115270)
1. "Paradoxical" arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease.
Sondag M; Verhoeven F; Guillot X; Prati C; Briot C; Vuitton L; Koch S; Wendling D
Joint Bone Spine; 2018 Jan; 85(1):133-134. PubMed ID: 28115270
[No Abstract] [Full Text] [Related]
2. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
3. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
4. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
[TBL] [Abstract][Full Text] [Related]
5. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
Shivaji UN; Sharratt CL; Thomas T; Smith SCL; Iacucci M; Moran GW; Ghosh S; Bhala N
Aliment Pharmacol Ther; 2019 Mar; 49(6):664-680. PubMed ID: 30735257
[TBL] [Abstract][Full Text] [Related]
6. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.
Chen Y; Sun J; Yang Y; Huang Y; Liu G
Clin Rheumatol; 2016 Jan; 35(1):1-18. PubMed ID: 26573205
[TBL] [Abstract][Full Text] [Related]
7. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
8. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.
Cheon JH
J Gastroenterol Hepatol; 2017 Apr; 32(4):769-777. PubMed ID: 27723166
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population.
Lian F; Zhou J; Wei C; Wang Y; Xu H; Liang L; Yang X
Clin Rheumatol; 2015 Nov; 34(11):1913-20. PubMed ID: 26070537
[TBL] [Abstract][Full Text] [Related]
10. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
[No Abstract] [Full Text] [Related]
11. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
[TBL] [Abstract][Full Text] [Related]
13. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.
Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
J Gastroenterol Hepatol; 2018 Jan; 33(1):20-29. PubMed ID: 29023903
[TBL] [Abstract][Full Text] [Related]
14. [Paradoxical psoriasis induced by anti-TNF - a clinical challenge].
Nidegger A; Mylonas A; Conrad C
Rev Med Suisse; 2019 Mar; 15(644):668-671. PubMed ID: 30916904
[TBL] [Abstract][Full Text] [Related]
15. Are anti-TNF drugs safe for pregnant women with inflammatory bowel disease?
Brennan GT; Duong A; Nguyen ET; Nguyen DL
Cleve Clin J Med; 2018 Dec; 85(12):923-924. PubMed ID: 30526752
[No Abstract] [Full Text] [Related]
16. New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.
van Langenberg DR
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():10-1. PubMed ID: 26990680
[No Abstract] [Full Text] [Related]
17. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
18. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
19. Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data.
Üsküdar Cansu D; Üsküdar Teke H; Temel T; Ertürk A; Kahraman O; Korkmaz C
J Natl Med Assoc; 2019 Jun; 111(3):262-269. PubMed ID: 30389147
[TBL] [Abstract][Full Text] [Related]
20. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
